These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 38401779

  • 1. Cefazolin versus cloxacillin in methicillin-susceptible Staphylococcus aureus endocarditis: Too good to be true? Authors' reply.
    Herrera-Hidalgo L, de Alarcón A.
    Int J Infect Dis; 2024 May; 142():106979. PubMed ID: 38401779
    [No Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety of cefazolin versus cloxacillin in endocarditis due to methicillin-susceptible Staphylococcus spp.: a multicenter propensity weighted cohort study.
    Destrem AL, Maillard A, Simonet M, Simeon S, Contejean A, Vignau C, Pires L, Isnard M, Vitrat V, Delory T, Maillet M.
    Eur J Clin Microbiol Infect Dis; 2024 Aug; 43(8):1569-1577. PubMed ID: 38806841
    [Abstract] [Full Text] [Related]

  • 3. 'Comparative outcomes of cefazolin versus anti-staphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis multicentre French cohort study'-author's reply.
    Lecomte R, Deschanvres C, Coudol S, Wargny M, Camou F, Boutoille D.
    Clin Microbiol Infect; 2021 Aug; 27(8):1180-1181. PubMed ID: 33813113
    [No Abstract] [Full Text] [Related]

  • 4. Comparative effectiveness of empirical antibiotic treatments in methicillin-susceptible Staphylococcus aureus infective endocarditis: A post hoc analysis of a prospective French cohort study.
    Lecomte R, Deschanvres C, Bourreau A, Ruffier d'Epenoux L, Le Turnier P, Gaborit B, Chauveau M, Michel M, Le Tourneau T, Bémer P, Corvec S, Boutoille D.
    Int J Infect Dis; 2024 May; 142():106989. PubMed ID: 38428479
    [Abstract] [Full Text] [Related]

  • 5. Cefazolin versus cloxacillin as definitive antibiotic therapy for methicillin-susceptible Staphylococcus aureus spinal epidural abscess: a retrospective cohort study.
    Bai AD, Findlater A, Irfan N, Singhal N, Loeb M.
    Int J Antimicrob Agents; 2021 Nov; 58(5):106429. PubMed ID: 34469802
    [Abstract] [Full Text] [Related]

  • 6. Adjunctive Clavulanic Acid Abolishes the Cefazolin Inoculum Effect in an Experimental Rat Model of Methicillin-Sensitive Staphylococcus aureus Endocarditis.
    Miller WR, Singh KV, Arias CA, Murray BE.
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30150459
    [Abstract] [Full Text] [Related]

  • 7. Cefazolin vs cloxacillin in MSSA endocarditis: too good to be true?
    Buis DTP.
    Int J Infect Dis; 2024 May; 142():106978. PubMed ID: 38401781
    [No Abstract] [Full Text] [Related]

  • 8. Re: 'Comparative outcomes of cefazolin versus anti-staphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis multicentre French cohort study' by Lecomte et al.
    Buis DTP.
    Clin Microbiol Infect; 2021 Aug; 27(8):1179. PubMed ID: 33581355
    [No Abstract] [Full Text] [Related]

  • 9. Prevalence of a cefazolin inoculum effect associated with blaZ gene types, and clinical outcomes among methicillin-susceptible Staphylococcus aureus blood isolates of patients with infective endocarditis.
    Bourreau A, Le Mabecque V, Broquet A, Caillon J.
    Infect Dis Now; 2023 Feb; 53(1):104626. PubMed ID: 36184048
    [Abstract] [Full Text] [Related]

  • 10. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study.
    Lecomte R, Bourreau A, Deschanvres C, Issa N, Le Turnier P, Gaborit B, Chauveau M, Leroy AG, Le Tourneau T, Caillon J, Camou F, Boutoille D.
    Clin Microbiol Infect; 2021 Jul; 27(7):1015-1021. PubMed ID: 32950711
    [Abstract] [Full Text] [Related]

  • 11. Comparison of ceforanide, cefazolin, methicillin, and nafcillin in Staphylococcus aureus endocarditis therapy in rabbits.
    Carrizosa J, Kobasa WD, Kaye D.
    Antimicrob Agents Chemother; 1980 Oct; 18(4):562-5. PubMed ID: 7447418
    [Abstract] [Full Text] [Related]

  • 12. Prolonged cefazolin course for treatment of methicillin susceptible staphylococcus species infections and the impact on the emergence of multidrug-resistant bacteria during cloxacillin shortage.
    Vareil MO, Barret A, Vinclair C, Guerpillon B, Leyssene D, Jaouen AC, Alleman L, Wille H.
    Infect Dis Now; 2021 May; 51(3):304-307. PubMed ID: 33934810
    [Abstract] [Full Text] [Related]

  • 13. Empirical use of β-lactam/β-lactamase inhibitor combinations does not increase mortality compared with cloxacillin and cefazolin in methicillin-susceptible Staphylococcus aureus bacteraemia: a propensity-weighted cohort study.
    Willekens R, Puig-Asensio M, Suanzes P, Fernández-Hidalgo N, Larrosa MN, González-López JJ, Rodríguez-Pardo D, Pigrau C, Almirante B.
    J Antimicrob Chemother; 2022 Jul 28; 77(8):2288-2295. PubMed ID: 35552420
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of cloxacillin versus cefazolin for methicillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): study protocol for a randomised, controlled, non-inferiority trial.
    Burdet C, Loubet P, Le Moing V, Vindrios W, Esposito-Farèse M, Linard M, Ferry T, Massias L, Tattevin P, Wolff M, Vandenesch F, Grall N, Quintin C, Mentré F, Duval X, Lescure FX, CloCeBa study group.
    BMJ Open; 2018 Sep 01; 8(8):e023151. PubMed ID: 30173161
    [Abstract] [Full Text] [Related]

  • 15. Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study.
    Lefèvre B, Hoen B, Goehringer F, Sime WN, Aissa N, Alauzet C, Jeanmaire E, Hénard S, Filippetti L, Selton-Suty C, Agrinier N, for AEPEI study group (Association pour l’Etude et la Prévention de l’Endocardite Infectieuse).
    Eur J Clin Microbiol Infect Dis; 2021 Dec 01; 40(12):2605-2616. PubMed ID: 34383175
    [Abstract] [Full Text] [Related]

  • 16. Treatment of experimental Staphylococcus aureus endocarditis: comparison of cephalothin, cefazolin, and methicillin.
    Carrizosa J, Santoro J, Kaye D.
    Antimicrob Agents Chemother; 1978 Jan 01; 13(1):74-7. PubMed ID: 626493
    [Abstract] [Full Text] [Related]

  • 17. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort.
    Herrera-Hidalgo L, Muñoz P, Álvarez-Uría A, Alonso-Menchén D, Luque-Marquez R, Gutiérrez-Carretero E, Fariñas MDC, Miró JM, Goenaga MA, López-Cortés LE, Angulo-Lara B, Boix-Palop L, de Alarcón A, Grupo de Apoyo al Manejo de la Endocarditis Infecciosa en España (GAMES) Cohort Investigators.
    Int J Infect Dis; 2023 Dec 01; 137():134-143. PubMed ID: 37926195
    [Abstract] [Full Text] [Related]

  • 18. Cloxacillin induced agranulocytosis: A rare adverse event of a commonly used antibiotic.
    Mani SSR, Iyyadurai R.
    Int J Immunopathol Pharmacol; 2017 Sep 01; 30(3):297-301. PubMed ID: 28786715
    [Abstract] [Full Text] [Related]

  • 19. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue.
    Nannini EC, Singh KV, Murray BE.
    Clin Infect Dis; 2003 Nov 01; 37(9):1194-8. PubMed ID: 14557964
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats.
    Cantoni L, Wenger A, Glauser MP, Bille J.
    J Infect Dis; 1989 May 01; 159(5):989-93. PubMed ID: 2708846
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.